Clinical Trial Update: The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating denosumab to reduce periprosthetic bone loss in total knee arthroplasty, with the study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Resorption

Drugs mentioned

• Denosumab (Prolia/Xgeva) (denosumab)

Snippet

Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Conditions: Bone Resorption | Phase 4 | Status: COMPLETED